Cantor Fitzgerald Lifts Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Arvinas in a report released on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.56) per share for the year, up from their prior estimate of ($2.71). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The company's quarterly revenue was up 646.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.97) earnings per share.

Several other analysts have also recently issued reports on ARVN. Piper Sandler reissued an "overweight" rating and issued a $14.00 target price (down from $24.00) on shares of Arvinas in a research note on Friday, May 2nd. Truist Financial reiterated a "hold" rating and set a $11.00 price objective (down previously from $21.00) on shares of Arvinas in a research report on Monday, May 5th. Stifel Nicolaus cut their price target on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a report on Wednesday, February 12th. Wedbush lowered Arvinas from an "outperform" rating to a "neutral" rating and dropped their price objective for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. Finally, The Goldman Sachs Group dropped their target price on Arvinas from $12.00 to $8.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.91.

Arvinas Stock Performance

ARVN traded down $0.29 during trading on Thursday, reaching $6.23. The stock had a trading volume of 1,803,167 shares, compared to its average volume of 1,298,182. The stock has a market cap of $454.73 million, a PE ratio of -2.25 and a beta of 2.21. Arvinas has a one year low of $5.94 and a one year high of $37.38. The business has a 50-day moving average of $8.43 and a 200-day moving average of $16.55.

Insider Buying and Selling

In other news, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This represents a 5.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at approximately $945,097.57. This represents a 7.30% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,230 shares of company stock worth $769,402. 4.73% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new position in Arvinas in the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Arvinas by 965.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock valued at $33,000 after acquiring an additional 4,219 shares in the last quarter. CWM LLC lifted its position in shares of Arvinas by 2,317.5% in the 1st quarter. CWM LLC now owns 7,615 shares of the company's stock valued at $53,000 after acquiring an additional 7,300 shares in the last quarter. KBC Group NV lifted its position in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after acquiring an additional 1,255 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new stake in shares of Arvinas in the 1st quarter valued at approximately $77,000. 95.19% of the stock is currently owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.